FS015

FS015 is a preclinical-stage therapeutic candidate being developed by Foreseen Biotechnology for the treatment of solid tumors. The asset was discovered using the company's proprietary AI-driven proteomics platform, which identifies novel tumor-associated antigens by analyzing high-throughput mass spectrometry data from clinical samples. While the specific molecular target and modality (such as a monoclonal antibody or antibody-drug conjugate) have not been publicly disclosed, FS015 represents a key part of Foreseen's pipeline of precision oncology therapeutics aimed at addressing unmet needs in solid tumor indications.